Literature DB >> 18317449

Eliminating epigenetic barriers induces transient hormone-regulated gene expression in estrogen receptor negative breast cancer cells.

L Fleury1, M Gerus, A C Lavigne, H Richard-Foy, K Bystricky.   

Abstract

In breast cancer, approximately one-third of tumors express neither the estrogen receptor (ERalpha) nor estrogen-regulated genes such as the progesterone receptor gene (PR). Our study provides new insights into the mechanism allowing hormone-activated expression of ERalpha target genes silenced in ERalpha-negative mammary tumor cells. In cell lines derived from ERalpha-negative MDA-MB231 cells, stable expression of different levels of ERalpha from a transgene did not result in transcription of PR. A quantitative comparative analysis demonstrates that inhibiting DNA methyltransferases using 5-aza-2'-deoxycytidine or specific disruption of DNMT1 by small interfering RNAs and treatment with the histone-deacetylase inhibitor trichostatin A enabled ERalpha-mediated hormone-dependent expression of endogenous PR. We show that demethylation of a CpG island located in the first exon of PR was a prerequisite for ERalpha binding to these regulatory sequences. Although not a general requirement, DNA demethylation is also necessary for derepression of a subset of ERalpha target genes involved in tumorigenesis. PR transcription did not subsist 4 days after removal of the DNA methyltransferase blocking agents, suggesting that hormone-induced expression of ERalpha target genes in ERalpha-negative tumor cells is transient. Our observations support a model where an epigenetic mark confers stable silencing by precluding ERalpha access to promoters.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18317449     DOI: 10.1038/onc.2008.41

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  12 in total

1.  The faah gene is the first direct target of estrogen in the testis: role of histone demethylase LSD1.

Authors:  Paola Grimaldi; Mariangela Pucci; Sara Di Siena; Daniele Di Giacomo; Valentina Pirazzi; Raffaele Geremia; Mauro Maccarrone
Journal:  Cell Mol Life Sci       Date:  2012-07-17       Impact factor: 9.261

2.  Reptin and Pontin oligomerization and activity are modulated through histone H3 N-terminal tail interaction.

Authors:  Richard Queval; Christophe Papin; Mathieu Dalvai; Kerstin Bystricky; Odile Humbert
Journal:  J Biol Chem       Date:  2014-10-21       Impact factor: 5.157

3.  Progesterone receptor isoform-specific promoter methylation: association of PRA promoter methylation with worse outcome in breast cancer patients.

Authors:  Thushangi N Pathiraja; Priya B Shetty; Jaroslav Jelinek; Rong He; Ryan Hartmaier; Astrid L Margossian; Susan G Hilsenbeck; Jean-Pierre J Issa; Steffi Oesterreich
Journal:  Clin Cancer Res       Date:  2011-04-01       Impact factor: 12.531

Review 4.  The role of histone modifications and variants in regulating gene expression in breast cancer.

Authors:  Mathieu Dalvai; Kerstin Bystricky
Journal:  J Mammary Gland Biol Neoplasia       Date:  2010-02-04       Impact factor: 2.673

5.  Epigenetic Therapy in Breast Cancer.

Authors:  Maryam B Lustberg; Bhuvaneswari Ramaswamy
Journal:  Curr Breast Cancer Rep       Date:  2011-03

6.  Activation of estrogen-responsive genes does not require their nuclear co-localization.

Authors:  Silvia Kocanova; Elizabeth A Kerr; Sehrish Rafique; Shelagh Boyle; Elad Katz; Stephanie Caze-Subra; Wendy A Bickmore; Kerstin Bystricky
Journal:  PLoS Genet       Date:  2010-04-22       Impact factor: 5.917

Review 7.  Epigenetic targeting in breast cancer: therapeutic impact and future direction.

Authors:  M B Lustberg; B Ramaswamy
Journal:  Drug News Perspect       Date:  2009-09

8.  Estradiol differentially induces progesterone receptor isoforms expression through alternative promoter regulation in a mouse embryonic hypothalamic cell line.

Authors:  Edgar Ricardo Vázquez-Martínez; Ignacio Camacho-Arroyo; Angel Zarain-Herzberg; María Carmen Rodríguez; Luciano Mendoza-Garcés; Patricia Ostrosky-Wegman; Marco Cerbón
Journal:  Endocrine       Date:  2015-12-16       Impact factor: 3.633

Review 9.  Epigenetic regulation in estrogen receptor positive breast cancer--role in treatment response.

Authors:  Thushangi N Pathiraja; Vered Stearns; Steffi Oesterreich
Journal:  J Mammary Gland Biol Neoplasia       Date:  2010-01-27       Impact factor: 2.673

10.  Activation of p21 by HDAC inhibitors requires acetylation of H2A.Z.

Authors:  Luca Bellucci; Mathieu Dalvai; Silvia Kocanova; Fatima Moutahir; Kerstin Bystricky
Journal:  PLoS One       Date:  2013-01-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.